KR970705403A - 비독성 경구용 어쥬번트로써 효과적인 장독소 돌연변이체(mutant enterotoxin effective as a non-toxic oral adjuvant) - Google Patents

비독성 경구용 어쥬번트로써 효과적인 장독소 돌연변이체(mutant enterotoxin effective as a non-toxic oral adjuvant)

Info

Publication number
KR970705403A
KR970705403A KR1019970701224A KR19970701224A KR970705403A KR 970705403 A KR970705403 A KR 970705403A KR 1019970701224 A KR1019970701224 A KR 1019970701224A KR 19970701224 A KR19970701224 A KR 19970701224A KR 970705403 A KR970705403 A KR 970705403A
Authority
KR
South Korea
Prior art keywords
vaccine
composition
antigen
method
enterotoxin
Prior art date
Application number
KR1019970701224A
Other languages
English (en)
Other versions
KR100399258B1 (ko
Inventor
죤 디 클레멘츠
보니 엘. 디킨슨
Original Assignee
폴 지. 다이먼트
더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/296,848 priority Critical patent/US6019982A/en
Priority to US296,848 priority
Application filed by 폴 지. 다이먼트, 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 filed Critical 폴 지. 다이먼트
Publication of KR970705403A publication Critical patent/KR970705403A/ko
Application granted granted Critical
Publication of KR100399258B1 publication Critical patent/KR100399258B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/381Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a virus
    • Y02A50/384Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a virus of the genus Flavivirus
    • Y02A50/389Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a virus of the genus Flavivirus the disease being Japanese encephalitis
    • Y02A50/39Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a virus of the genus Flavivirus the disease being Japanese encephalitis the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/398Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria
    • Y02A50/399Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria of the genus Borrellia
    • Y02A50/401Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria of the genus Borrellia the bacteria being Borrelia burgdorferi, i.e. Lyme disease or Lyme borreliosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/398Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria
    • Y02A50/402Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria of the genus Rickettsia, Orientia, Ehrlichia, Neorickettsia, Neoehrlichia or Anaplasma, i.e. Rickettsial diseases, e.g. spotted fever
    • Y02A50/403Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria of the genus Rickettsia, Orientia, Ehrlichia, Neorickettsia, Neoehrlichia or Anaplasma, i.e. Rickettsial diseases, e.g. spotted fever the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • Y02A50/412Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/417Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a helminth, i.e. Helmanthiasis
    • Y02A50/423Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a helminth, i.e. Helmanthiasis the helminth being a trematode flatworm of the genus Schistosoma, i.e. Schistosomiasis or bilharziasis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462The waterborne disease being caused by a virus
    • Y02A50/463The waterborne disease being caused by a virus the virus being the Hepatitis A virus [HAV]
    • Y02A50/464The waterborne disease being caused by a virus the virus being the Hepatitis A virus [HAV] the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462The waterborne disease being caused by a virus
    • Y02A50/465The waterborne disease being caused by a virus the virus being the poliovirus, i.e. Poliomyelitis or Polio
    • Y02A50/466The waterborne disease being caused by a virus the virus being the poliovirus, i.e. Poliomyelitis or Polio the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/471The waterborne disease being caused by a bacteria the bacteria being Vibrio cholerae, i.e. Cholera
    • Y02A50/472The waterborne disease being caused by a bacteria the bacteria being Vibrio cholerae, i.e. Cholera the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/475The waterborne disease being caused by a bacteria of the genus Shigella, i.e. Dysentery
    • Y02A50/476The waterborne disease being caused by a bacteria of the genus Shigella, i.e. Dysentery the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/479The waterborne disease being caused by a bacteria of the genus Leptospira, i.e. Leptospirosis
    • Y02A50/48The waterborne disease being caused by a bacteria of the genus Leptospira, i.e. Leptospirosis the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/825Bacteria

Abstract

독성은 상실하였으나 이의 면역학적 활성은 보유하고 있는 대장균 열-불안정한 장독소의 신규한 돌연변이 형으로된 조성물과 이의 용도를 제공한다. 이와 같은 장독소는 경구 백신 준비물의 일부로써 투여하였을 때 항원에 대한 증가된 면역반응을 얻기 위해 무관한 항원과 복합하여 사용될 수도 있다.

Description

비독성 경구용 어쥬번트로써 효과적인 장독소 돌연변이체(MUTANT ENTEROTOXIN EFFECTIVE AS A NON-TOXIC ORAL ADJUVANT)

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (22)

  1. 면역학적 어쥬번트 활성을 가지면서 NAD-아그마틴-ADP-리보실 전달효소 검사에 의해 측정하였을 때 ADP-리보실화 효소활성이 부족한 대장균 열-불안정한 장독소 할로톡신의 돌연변이 형으로 구성된 것을 특징으로 하는 조성물.
  2. 할로톡신의 A 소단위가 트립신에 의해 절단되진 않은 면역학적 어쥬벤트 활성이 있는 대장균 열 불안정한 장독소 할로톡신의 돌연변이 형으로 구성된 것을 특징으로 하는 조성물.
  3. 제1항 또는 제2항에 있어서, 조성물은 대장균 열-불안정한 장독소의 A 소단위와 B 소단위 모드를 발현하고 ATCC에 기탁되어 기탁번호가 696883인 대장균 LTR192G에 포함된 플라스미드 pBD95에 의해 인코드되는 것을 특징으로 하는 조성물.
  4. 제1항 내지 2항에 따른 조성물과 복합된 항원으로 구성된 것을 특징으로 하는 백신 조성물.
  5. 제4항에 있어서, 항원은 인플루엔자 백신, 바리셀라 백신, 디프테리아 독소, 테타누스 독소, 페로트시스 백신 일본 엔세팔리티스 백신, 페르투시스, 디프테이아와 테타느스독소의 혼합형 백신, 라임 질병백신, 폴리오백신, 말라리아 백신, 허피스 백신, HIV 백신, 파필로마 바이러스 백신, 헤파타이티스 B백신, 로타 백신, 캄필로박터 백신,콜레라 백신,장병원성 대장균 백신, 장독소 대장균 백신, 쉬스토소마이시스 백신, 홍역 백신, 루베라 백신, 멈프스 백신, 홍역, 루벨라와 멈프스 혼합형 백신 그리고 미코플라스마 백신에서 선택되는 것을 특징으로 하는 백신 조성물.
  6. 숙주에서 병원균에 보호성 면역반응을 만드는데 유용한 조성물에 있어서, 제1항 또는 2항에 따른 조성물의 어쥬번트 효과량과 항원 효과량의 혼합물로 구성된 것을 특징으로 하는 조성물.
  7. 병원균에 대한 숙주에서 보호성 면역 반응을 만드는데 유용한 키트에 있어서, 두가지 성분으로 구성되는 데 a) 효과량의 항원과 b) NAD-아크마틴 ADP-리보실전달 효소 검사에 의해 측정하였을 때 ADP-리보실화 효소 활성이 부족하나 면역학적 어쥬번트 활성을 가지는 대장균 열-불안정한 장독소 홀로톡신 돌연변이체의 어쥬번트 효과량으로 구성되고 이때, 이 두성분을 경구을 투여가능한 담체에 있고 서로 혼합시킨후 함께 투여하거나 또는 짧은 시간 간격내에서 별도로 투여될 수 있는 것을 특징으로 하는 키트.
  8. 제1항 또는 6항에 있어서, A소단위는 트립신에 의해 절단되지 않는 것을 특징으로 하는 조성물.
  9. 제4항에 있어서, A소단위는 트립신에 의해 절단되지 않는 것을 특징으로 하는 키트.
  10. 제7항에 있어서, A소단위는 트립신에 의해 절단되지 않는 것을 특징으로 하는 키트.
  11. 제1항 또는 6항에 있어서, 야생형 대장균 열-불안정한 장독소의 아미노산 Arg192는 Gly192로 대체되는 것을 특징으로 하는 조성물.
  12. 제4항에 있어서, 야생형 대장균 열-불안정한 장독소의 아미노산 Arg192는 Gly192로 대체되는 것을 특징으로 하는 조성물.
  13. 제7항에 있어서, 야생형 대장균 열-불안정한 장독소의 아미노산 Arg192는 Gly192로 대체되는 것을 특징으로 하는 조성물.
  14. 병원균에 대한 숙주에서 보호성 면역 반응을 만드는데 방법에 있어서, 효과량의 항원과 NAD-아크마틴 ADP-리보실전달 효소 검사에 의해 측정하였을 때 ADP-리보실화 효소 활성이 부족하나 면역학적 어쥬번트 활성을 가지는 대장균 열-불안정한 장독소 홀로톡신 돌연변이체의 어쥬번트 효과량을 경구을 투여가능한 담체에 있고 서로 혼합시킨후 함께 투여하는 것을 특징으로 하는 방법.
  15. 제14항에 있어서, 혈청반응이 생산되는 것을 특징으로 한는 방법.
  16. 제14항에 있어서, 점막반응이 생산되는 것을 특징으로 한는 방법.
  17. 제14항에 있어서, 항원이 연속 촉진주사가 제공되는 것을 특징으로 하는 방법.
  18. 제14항에 있어서, 항원이 박테리아, 바이러스, 프로토조아, 곰팡이, 기생충, 그리고 다른 미생물 병원균에서 유도되는 것을 특징으로 하는 방법.
  19. 제14항에 있어서, 혼합물은 단일 약량으로 수송되는 것을 특징으로 하는 방법.
  20. 장독소 발테리아 유기체에 대한 보호성 면역 반응을 유도하는 방법에 있어서, 장독소 박테리아 유기체에 대한 백신성분으로써 mLT를 이용하는 것으로 구성된 것을 특징으로 하는 방법.
  21. 제20항에 있어서, 장독성 박테리아 유기체는 콜레라-형 독소를 발현하는 장독성 박테리아 유기체에서 선택되는 것을 특징으로 하는 방법.
  22. 제20항에 있어서, 장독성 박테리아 유기체는 대장균spp와 비브리오 spp에서 선택되는 것을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR10-1997-0701224A 1994-08-26 1995-07-18 비독성경구용어쥬번트로써효과적인장독소돌연변이체 KR100399258B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US08/296,848 US6019982A (en) 1994-08-26 1994-08-26 Mutant enterotoxin effective as a non-toxic oral adjuvant
US296,848 1994-08-26

Publications (2)

Publication Number Publication Date
KR970705403A true KR970705403A (ko) 1997-10-09
KR100399258B1 KR100399258B1 (ko) 2003-12-31

Family

ID=23143827

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1997-0701224A KR100399258B1 (ko) 1994-08-26 1995-07-18 비독성경구용어쥬번트로써효과적인장독소돌연변이체

Country Status (23)

Country Link
US (2) US6019982A (ko)
EP (1) EP0777490B1 (ko)
JP (1) JP3860208B2 (ko)
KR (1) KR100399258B1 (ko)
CN (1) CN1182868C (ko)
AT (1) AT326231T (ko)
AU (1) AU709779B2 (ko)
BR (1) BR9508633A (ko)
CA (1) CA2198586C (ko)
CZ (1) CZ298131B6 (ko)
DE (2) DE69534992T2 (ko)
DK (1) DK0777490T3 (ko)
ES (1) ES2265148T3 (ko)
FI (1) FI120137B (ko)
HU (1) HU222985B1 (ko)
MX (1) MX9701445A (ko)
NO (1) NO317942B1 (ko)
NZ (1) NZ291262A (ko)
PL (1) PL182667B1 (ko)
PT (1) PT777490E (ko)
RU (1) RU2160606C2 (ko)
WO (1) WO1996006627A1 (ko)
ZA (1) ZA9506412B (ko)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
DE69334197T2 (de) * 1992-03-02 2008-12-11 Novartis Vaccines And Diagnostics S.R.L. Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik
DE69434000D1 (de) 1993-10-05 2004-10-21 Celltech Pharmaceuticals Ltd Impfstoffzusammensetzungen
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
EP0769018B1 (en) * 1994-07-01 2002-12-18 Chiron Corporation Helicobacter proteins and vaccines
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
ES2283012T3 (es) * 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
EP0998557A2 (en) * 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
AU3089599A (en) * 1998-03-18 1999-10-11 Smithkline Beecham Corporation Production of purified mutant enterotoxin for use as an adjuvant
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
GB9819484D0 (en) * 1998-09-07 1998-10-28 Univ Bristol Therapeutic agents
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US6589529B1 (en) * 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
DE60039113D1 (de) * 1999-03-03 2008-07-17 Kitasato Inst Impfstoff-präparation die eine fettsäure als inhaltstoff enthält
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
US7722887B1 (en) * 1999-09-15 2010-05-25 Mogam Biotechnology Research Institute Detoxified mutants of escherichia coli heat-labile enterotoxin
JP4889175B2 (ja) * 1999-10-18 2012-03-07 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 感染性因子に対する免疫応答を刺激するための組成物および方法
ES2306670T3 (es) 1999-10-22 2008-11-16 Sanofi Pasteur Limited Procedimiento de induccion y/o intensificacion de la respuesta inmunitaria frente a antigenos tumorales.
EP1792995A3 (en) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia secretory locus orf and uses thereof
AT346925T (de) 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
WO2002016440A2 (en) 2000-08-25 2002-02-28 Aventis Pasteur Limited Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections
AU8020801A (en) 2000-08-31 2002-03-13 Kitasato Inst Vaccine preparation containing fatty acid as component
WO2002064162A2 (en) * 2001-02-13 2002-08-22 Government Of The United States, As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
EP2316482A1 (en) 2001-03-19 2011-05-04 Intercell USA, Inc. Transcutaneous immunostimulation
US7285281B2 (en) 2001-06-07 2007-10-23 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
KR100877258B1 (ko) 2001-06-07 2009-01-12 더 거번먼트 오브 더 유나이티드 스테이츠 오브 아메리카 애즈 레프리젠티드 바이 더 유니폼드 서비시즈 유니버시티 오브 더 헬쓰 사이언시즈 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
US20050175629A1 (en) * 2001-08-31 2005-08-11 Giuseppe Del Giudice Helicobacter pylori vaccination
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
WO2003101484A1 (en) * 2002-05-31 2003-12-11 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
WO2004020585A2 (en) * 2002-08-27 2004-03-11 Dow Agrosciences Llc Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry
WO2004043286A2 (en) * 2002-11-14 2004-05-27 Pfizer Products Inc. Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
US20040171565A1 (en) * 2003-02-14 2004-09-02 David Hone DNA vaccines that expresses mutant ADP-ribosyltransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity
US20060069052A1 (en) * 2003-02-14 2006-03-30 David Hone DNA vaccines that expresses mutant ADP-ribosyItransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity
WO2005019412A2 (en) 2003-05-20 2005-03-03 New York University Mucosal immunization to prevent prion infection
US8685718B2 (en) * 2003-05-20 2014-04-01 New York University Mucosal immunization to prevent prion infection
EP2502999A3 (en) 2006-03-03 2013-01-23 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
BRPI0414073A (pt) 2003-09-02 2006-10-24 Glaxosmithkline Biolog Sa método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
EP1708744A4 (en) * 2003-12-09 2009-07-15 Intercell Usa Inc Gm1 binding deficient exotoxins for use as immunoadjuvants
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CN100387719C (zh) 2005-05-09 2008-05-14 中国农业科学院生物技术研究所;深圳市农科集团公司 编码大肠杆菌热敏毒素基因及其表达载体和用途
AU2006289626A1 (en) * 2005-09-09 2007-03-15 Universitat Zurich Antigens for vaccination against and detection of Mycoplasma suis
WO2007091911A1 (fr) * 2006-02-09 2007-08-16 Institut Problem Pererabotki Uglevodorodov Sibirskogo Otdeleniya Rossiiskoi Akademii Nauk Sorbant, procédé de fabrication et procédé de séchage d'hydrocarbures
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
EP2170377B1 (en) * 2007-07-18 2015-03-04 Development Center For Biotechnology Mutated e. coli heat-labile enterotoxin
AU2007353789B2 (en) 2007-05-23 2014-05-22 The Uab Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
DE102007037301A1 (de) * 2007-08-07 2009-02-12 BSH Bosch und Siemens Hausgeräte GmbH Hausgeräteanordnung
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US8821885B2 (en) 2007-08-27 2014-09-02 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
NZ583750A (en) 2007-09-11 2012-05-25 Univ Guelph Novel polysaccharide immunogens from clostridium difficile
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
DK2535428T3 (en) 2007-10-01 2015-11-23 Longhorn Vaccines & Diagnostics Llc Biological prøvesamlings- and transport system, and methods of using
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US8444994B2 (en) * 2008-07-01 2013-05-21 The Albert B. Sabin Vaccine Institute Multivalent antihelminthic vaccine
US7927586B2 (en) * 2008-07-08 2011-04-19 South Dakota State University Vaccine for porcine post-weaning diarrhea caused by enterotoxigenic Escherichia coli
EP2376526A4 (en) 2008-12-24 2013-02-27 Kingdom Of The Netherlands Represented By The Min Ister Of Health Welfare & Sport On Behalf Of The M Modified streptococcus pneumoniae pneumolysin (ply) polypeptides
TW201103980A (en) 2009-07-08 2011-02-01 Abbott Biologicals Bv Viral vaccine and use thereof
EP2668201A2 (en) 2011-01-28 2013-12-04 Sanofi Pasteur SA Immunological compositions comprising hiv gp41 polypeptide derivatives
CN104203272A (zh) 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 复合抗原序列及疫苗
JP6014666B2 (ja) 2012-06-20 2016-10-25 国立大学法人 東京大学 粘膜免疫賦活化剤及びhpv感染症治療用経口医薬組成物
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
CA2985652A1 (en) 2015-05-14 2016-11-17 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
CN108431214A (zh) 2015-10-05 2018-08-21 美国政府(由卫生和人类服务部的部长所代表) 人轮状病毒g9p[6]毒株和作为疫苗的用途
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 国立予防衛生研究所長 ワクチン製剤
IL101715A (en) * 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant

Also Published As

Publication number Publication date
DK0777490T3 (da) 2006-09-18
AU709779B2 (en) 1999-09-09
EP0777490B1 (en) 2006-05-17
CZ56297A3 (en) 1997-10-15
ES2265148T3 (es) 2007-02-01
WO1996006627A1 (en) 1996-03-07
DE69534992T2 (de) 2007-05-10
JP3860208B2 (ja) 2006-12-20
DE69534992D1 (de) 2006-06-22
FI970799A0 (fi) 1997-02-26
FI970799A (fi) 1997-04-24
CZ298131B6 (cs) 2007-07-04
KR100399258B1 (ko) 2003-12-31
US6019982A (en) 2000-02-01
JPH10505059A (ja) 1998-05-19
BR9508633A (pt) 1997-09-30
NO970993D0 (no) 1997-03-04
HU222985B1 (hu) 2004-01-28
HUT77869A (hu) 1998-09-28
NO317942B1 (no) 2005-01-10
CN1182868C (zh) 2005-01-05
AT326231T (de) 2006-06-15
FI120137B1 (ko)
CA2198586A1 (en) 1996-03-07
ZA9506412B (en) 1996-03-11
US6440423B1 (en) 2002-08-27
FI970799D0 (ko)
PL182667B1 (xx) 2002-02-28
AU3233795A (en) 1996-03-22
PL318930A1 (en) 1997-07-21
EP0777490A4 (en) 1998-11-18
NO970993L (no) 1997-04-25
CN1164191A (zh) 1997-11-05
PT777490E (pt) 2006-10-31
NZ291262A (en) 1999-02-25
EP0777490A1 (en) 1997-06-11
RU2160606C2 (ru) 2000-12-20
FI120137B (fi) 2009-07-15
CA2198586C (en) 2010-10-12
MX9701445A (es) 1998-05-31

Similar Documents

Publication Publication Date Title
DK0835663T3 (da) Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener
DE69434956D1 (de) Auf einer Emusion und MPL basierte Adjuvantien für Impfstoffe
DE69806408T2 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
ES2485940T3 (es) Combinación de vacunas contra Meningitis B/C
DE69331495T2 (de) Impfstoffe gegen neisseria meningitidis gruppe c
ES2182822T3 (es) Composiciones de polipeptidos inmunorreactivos del virus de la hepatitis c.
KR970706387A (ko) 항원성이 보강된 장내세균을 생산하는 방법과 이를 포함하는 방법(methods for producing enhanced antigenic enteric bacteria and vaccines comprising same)
CA2344740A1 (en) Mutant cholera holotoxin as an adjuvant
RU2012116119A (ru) Множественная вакцинация, включающая менингококки серогруппы с
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
SE8602855D0 (sv) Hylsformat inbeddningselement, serskilt for amputationsstumpar
DE69522984T2 (de) Europäische Vakzinstämme des Fortplanzungs-Atmungs-Syndromsvirus des Schweins
BR0313587A (pt) composições imunoestimuladoras e métodos de estimulação de uma resposta imune
AU4186189A (en) Influenza vaccine and novel adjuvants
CA2059692A1 (en) Pneumoccoccal polysaccharide conjugate vaccine
WO2000002522A3 (en) Anthrax vaccine
EA200000608A1 (ru) Предотвращение и лечение амилоидогенного заболевания
JPH04253703A (en) Process for enhancing resistance of aquatic animal to disease
WO2005037190A3 (en) Multiplex vaccines
CA2413163A1 (en) 3'-prodrugs of 2'-deoxy-.beta.-l-nucleosides
CA2031164A1 (en) Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
CA2076744A1 (en) Viral Agent Associated with Mystery Swine Disease
EP0362279A1 (en) Saponin adjuvant.
WO1999061056A3 (en) Methods and products for inducing mucosal immunity
EP0231209A1 (en) Virus vaccine.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110830

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20120827

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee